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Abstract
Background: Thirty thousand knee replacements are performed annually in the UK. There is
uncertainty as to the best surgical approach to the knee joint for knee arthroplasty. We planned a
randomised controlled trial to compare a standard medial parapatellar arthrotomy with sub-vastus
arthrotomy for patients undergoing primary total knee arthroplasty in terms of short and long term
knee function.
Methods: Patients undergoing primary total knee arthroplasty at the local NHS Trust are to be
recruited into the study. Patients are to be randomised into either the subvastus or medial
parapatellar approache to knee arthroplasty. The primary outcome measures will be the American
Knee Society and WOMAC Scores. The secondary outcome measures will be patient based
measures of EuroQol and SF-36. All outcomes will be measured pre-operatively, 1, 6, 12 and 52
weeks post-operatively. We will also review pain intensity using a pain and analgesia diary. Ease of
surgical exposure and complications will also be analysed.
Discussion: Evidence is lacking concerning the best surgical approach to the knee joint for patients
undergoing primary total knee replacement. This pragmatic randomised trial tests the hypothesis
that the sub-vastus approach is significantly superior to the standard medial parapatellar approach
in terms of short and long term knee function.
Background
There is general agreement about the value of knee
replacement surgery, with approximately 30,000 knee
replacements performed annually in the UK. However,
there is uncertainty as to the best surgical approach to the
knee joint.
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Total knee replacements through a standard medial para-
patellar arthrotomy [1] are routinely carried out. The sub-
vastus (southern) arthrotomy has been suggested as an
alternative [2]. There have been two previous published
trials of the sub-vastus approach versus a standard medial
parapatellar approach.
In the first of these [3], 20 patients undergoing bilateral
knee arthroplasty were studied, with follow-up at 1, 4 and
12 weeks post-operatively. The patients whose knee was
approached by the sub-vastus method showed 35% and
16% greater quadriceps strength at 1 week and 1 month
respectively. In addition, the authors highlighted several
anatomical advantages. The approach maintains the
medial parapatellar blood supply and preserves the exten-
sor mechanism [4-6]. Thus, theoretically, it decreases the
likelihood of patellar subluxation, fracture, or patellar
avascular necrosis (reported as having an incidence of
17%, 21% and 10% respectively) [7,8].
In the second of these trials [4], 41 consecutive primary
knee arthroplasties were studied with follow-up at 6
months. Patients who had the sub-vastus approach were
able to straight leg raise 4 days sooner (p = 0.008) and
used 40% less post-operative analgesia (p = 0.05). They
also spent on average 3 days less in hospital (p = 0.01).
The subvastus approach has also been reported to have
decreased wound complications, a shorter hospital stay, a
reduction in analgesia usage and an early return to func-
tion when compared to the standard median parapatellar
approach [2,4,9].
There were problems with the validity and quality of both
studies, as they were not truly randomised, and involved
only a small number of patients and follow-up was short.
Long term follow-up is needed to determine whether
potential short term benefits increase long term effective-
ness. A larger sample size will allow a wider range of out-
comes to be investigated (in particular knee function) and
a broader range of patients to be recruited to improve
external validity and allow for sub-group analysis (e.g. by
age and sex). Furthermore, involving more surgeons will
allow assessment of variation in outcome by individual
surgeons.
We propose, therefore, a fully randomised controlled trial,
with long-term follow-up, in a large sample population
with patient-based outcomes to compare the standard
approach with the sub-vastus approach in total knee
replacement.
Objectives
This trial proposes to:
1. study the effectiveness and efficiency at 1, 6, 12 and 52
weeks of a standard medial parapatellar arthrotomy com-
pared with a sub-vastus arthrotomy in primary total knee
replacement.
2. examine both clinical and economic outcomes of care
of a standard medial parapatellar arthrotomy compared
with a sub-vastus arthrotomy in primary total knee
replacement at 1, 6,12 and 52 weeks.
3. examine patient based outcomes of care (EuroQol [10],
WOMAC [11], pain (visual-analogue scale)) of a standard
medial parapatellar arthrotomy compared with a sub-vas-
tus arthrotomy in primary total knee replacement at 1,
6,12 and 52 weeks.
Trial summary
This study aims to compare the effectiveness and effi-
ciency of a standard medial parapatellar approach versus
a sub-vastus approach in total knee replacement and to
evaluate the clinical outcomes of care in each group. We
propose a randomised controlled trial, with follow-up at
52 weeks, in a large sample population of 230 patients
with patient based outcomes. The trial summary can be
seen in figure 1. Patients will be recruited at their pre-oper-
ative assessment with randomisation taking place on their
day of admission for surgery. Clinical and functional
assessments will be carried out by a research nurse and
physiotherapist respectively, pre and post-operatively,
with the physiotherapist unaware of the approach taken.
The primary outcome measure for the study is the Knee
Society Score [12] and this will be collected at baseline
and at 1, 6, 12 and 52 weeks post-operatively. Other out-
come measures will include patient based (EuroQol 5D
[10], WOMAC Index [11]), clinical (complications, blood
loss, use of analgesia) and functional (range of motion)
measures. Data will be analysed on an intention to treat
basis with the principal comparisons being the mean dif-
ference in the Knee Society Score between the two groups
at 1, 6, 12 and 52 weeks post-operatively.
Design
Study type
Randomised controlled trial comparing standard medial
parapatellar arthrotomy with a sub-vastus arthrotomy in
total knee replacement.
Participants
Participants will be patients undergoing primary bi (tib-
ial-femoral joint) or tri (tibial-femoral-patellar) compart-
mental knee replacement for any indications. These
patients will be recruited from North Staffordshire Hospi-
tal, Stoke on Trent.Trials 2006, 7:23 http://www.trialsjournal.com/content/7/1/23
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Treatment details
A Low Contact Stress knee prosthesis manufactured by
Depuy will be used. Both consultant orthopaedic sur-
geons and consultant-supervised Orthopaedic Specialist
Registrars will be eligible to perform each of the
approaches.
Skin incision
The prosthesis will be inserted via a mid-line skin incision
beginning over the medial portion of the quadriceps ten-
don, four inches above the upper border of the patella.
The incision will continue in a gentle curve following the
medial margin of the quadriceps tendon, patella and
patella tendon. It will then cross the upper end of the tibia
and end inferior to the tubercule of the tibia. Exposure of
the knee joint will then occur either by a standard medial
parapatellar arthrotomy [1] or sub-vastus arthrotomy [2].
Standard medial parapatellar approach
A straight incision will be made through the three layers
of fascia over the quadriceps and the patella tendons. The
synovia and deep aponeurosis will be divided medial to
the patella and the quadriceps tendon will be separated in
the line of its fibers just lateral to the insertion of the vas-
tus medialis. The patella tendon will be freed along its
medial border to the level of the tibial tubercule, exposing
the infrapatellar bursa. The patellar will be dislocated lat-
erally.
Sub-vastus approach
Fascia layer I will be incised inline with the mid-line skin
incision. At the level of the patella, it will be incised
slightly medially. Beginning proximally, the fascia layer I
will be raised off the perimuscular fascia of the vastus
medialis down to its insertion site. The inferior edge of the
vastus will be lifted off the periosteum and intermuscular
septum with blunt finger dissection for approximately 10
cm proximal to the adductor tubercle. The tendinous
insertion of the vastus medials will be incised about mid-
patella. Care will be taken not to incise the synovium. Lift-
ing the extensor mechanism anterior and lateral will allow
a curvilinear medial arthrotomy beginning in the suprap-
atellar pouch and ending at the tibial tubercule. Sharp soft
tissue release from the proximal tibia will be performed.
The patella will be everted laterally with the knee in full
extension. The knee will be flexed while the vastus medi-
alis will be bluntly dissected off intermuscular septum
proximally. If a lateral release is needed, it will be carried
out from the outside in, with the knee in full flexion.
Eligibility
A patient will be eligible if:
(i) They require a bi or tri compartmental knee replace-
ment
(ii) They require a unilateral knee replacement
(iii) They have given their informed consent
(iv) The surgeon has no clear preference for either of the
approaches
Flow Chart Figure 1
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A patient will be ineligible to enter the trial if:
(i) They need a revision knee replacement
(ii) They have had, or will require a major arthrotomy in
the other knee in a 12 month period
(iii) They have had previous open surgery in or around the
knee in the previous 12 months e.g. high tibial osteotomy,
femoral osteotomy, ORIF for fracture, patellar realign-
ment, patellectomy and open meniscectomy.
(iv) They require a bi-lateral knee replacement at a single
visit
(v) They have a valgus angle of ≥ 20°
Recruitment
Patients will be recruited over a 12 month period. Surgical
lists will be reviewed weekly to identify all patients
referred to the participating hospital centre and listed for
total knee replacement. Their notes will be screened prior
to their pre-operative outpatient appointment. At their
pre-operative visit patients will be informed of the nature
of the study by their consultant surgeon. Eligible patients
will be provided with an information leaflet explaining
the nature of the study to them. They will be invited to ask
questions regarding the research. Patients will then be
asked to return home and think about whether or not they
wish to participate. During the 4–6 week period following
their pre-operative visit and prior to admission for sur-
gery, patients will be contacted by the research nurse to
discuss their participation in the study and to address any
unanswered questions they may have. On the day of
admission, the patients will have a further opportunity to
discuss participation with the research nurse involved in
the trial. Those patients wishing to take part will be
invited to sign an informed consent form by their sur-
geon. Following consent being obtained, patients will be
randomised on their day of admission to either a sub-vas-
tus or medial parapatellar approach.
Randomisation
Patients will be randomised according to a minimisation
method using a telephone randomisation service. The
minimisation variables will be surgeon, and gender. Ran-
domisation will take place after informed consent will
have been given, eligibility criteria will have been
checked, and baseline measurements will have been
taken. The randomisation will take place on the day of
admission. This will be carried out at the co-ordinating
centre. At this telephone call, basic descriptive informa-
tion will be given (patient's name, sex, date of birth, hos-
pital and surgeon). After this phone call, the patient will
be considered irrevocably to have entered in the trial for
the purposes of the research.
Assessment of outcome
The primary outcome measure for this study will be the
Knee Society Score [12] at 52 weeks, and will be carried
out by a trained independent assessor (physiotherapist)
who will be blinded to the surgical approach taken.
Secondary outcomes – patient based
1. EuroQol-5D [10]. A simple, generic measure of health
outcome. It allows an accurate self-description of current
health related quality of life, assessing mobility, self-care,
usual activity level, pain/discomfort and anxiety/depres-
sion.
2. WOMAC Osteoarthritis Index [11]. An osteoarthritis
specific measure of health outcome, assessing pain, stiff-
ness and activity level.
3. SF-36 [13]. A comprehensive generic measure of health
outcome.
4. Time to normal activities/return to function (days/
weeks)
5. Pain (7 day pain diary – visual analogue scale 0–100)
Secondary outcomes – medical records
1. Complications (in hospital or requiring readmission
during 12 month follow-up)
2. Length of stay in hospital (days)
3. Tourniquet time (minutes)
4. Blood loss (litres)
5. Post-operative use of analgesia (7 day analgesia diary
recorded by nurse)
6. Surgeons ease of exposure score (VAS 0–100) – form
inserted in notes
Secondary outcomes – independently assessed by 
physiotherapist
1. Flexion/extension range of motion (degrees)
2. Time to straight leg raise (days)
Secondary outcomes – health economic
1. Cost of inpatient care including operative/diagnostic,
length of stay, length of operation staff costs, complica-
tions/re-admissions and consumablesTrials 2006, 7:23 http://www.trialsjournal.com/content/7/1/23
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Assessments/data collection
All trial proformas will be supplied in a separate booklet
and will form the basis of the patients case report form.
Assessment will be conducted pre, peri and post-opera-
tively. Data on the primary and all patient based and inde-
pendently assessed secondary outcome measures will be
collected at 1, 6, 12, and 52 weeks postoperatively. These
assessments are timed to coincide with routine clinical
practice.
Statistical considerations
Sample size
In a group of 86 patients undergoing total knee arthro-
plasty the mean 1 year post-operative Knee Society Score
was 172.2 with a standard deviation of 20 and a range of
98–200 [14]. To detect a 5% increase in the post-operative
Knee Society Score in the sub-vastus group compared to
the medial parapatellar group with a two sided signifi-
cance level of 5% and a power of 90% a sample size of 105
patients would be required in each group. An additional
10% will be recruited to each group to allow for any
patients lost to follow-up, giving a total sample size of
231.
Data analysis
Intention to treat analysis – all patients entered into the
trial will be followed up in the group to which they were
randomly allocated regardless of which treatment they
received. Continuous data will be analysed using repeated
measures analysis of variance while the chi square test will
be used to compare all categorical data. Baseline charac-
teristics of the group will be compared using appropriate
parametric and non parametric tests to ensure balance has
been achieved with randomisation.
The principal comparisons will be between:
a) Comparison of the mean total Knee Society Score
between the two groups at 1, 6, 12 and 52 weeks post-
operatively.
b) Comparison of all secondary outcome measures
between the two groups.
Protocol deviations
Any deviation from the agreed protocol will be recorded.
Any amendments that may be required once the trial has
been initiated will be submitted for ethics committee
approval prior to implementation.
Interim analyses and Data Monitoring Committee (DMC)
The first monitoring analysis of the primary end will be
performed once 50 patients have completed their 1 week
post-operative assessment. The data will be supplied to an
independent data monitoring committee (DMC), which
will be asked to give advice on whether the accumulated
data from this trial, justifies its continuation. The inde-
pendent DMC will comprise a statistician, an orthopaedic
surgeon, and a clinical researcher.
The decision to discontinue will only be made if the
results are likely to be convincing to a broad range of cli-
nicians including participants in the trial and the general
clinical community. A nominal significance level for stop-
ping the trial will be p <= 0.02 [15].
Ethical considerations
This study has obtained ethical approval from the North
Staffordshire Local Research Ethics Committee and Scien-
tific Merit Committee.
Informed consent
All eligible patients who agree to take part will sign an
informed consent form. They will confirm that they have
been given the information they require and that the
study has been explained to them. Once a patient has con-
sented to enter the trial, their GPs will be informed of their
patients' involvement in the study.
Confidentiality
Only the trial organisers/administrators will have access
to patients' notes and questionnaires. All recorded infor-
mation will be stored separately from patient names and
addresses.
Trial organisational structure
Trial co-ordination
The day to day management of the trial will be co-ordi-
nated from the local Musculoskeletal Research Depart-
ment. The co-ordinating centre will be responsible for:
a) Processing and analysis of the trial data
b) Monitoring of data collection
c) Ensure confidentiality and security of all trial forms and
data
d) Conduct data checking and cleaning
e) Interim and main analysis
Clinical co-ordination
At the start of the trial representatives from the clinical
centre along with the trial co-ordinator will visit surgeons
with the aim of getting commitment to recruit patients
into the study.
The Clinical Centre will:Trials 2006, 7:23 http://www.trialsjournal.com/content/7/1/23
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(i) establish the trial locally with the assistance of the trial
co-ordinator (for example getting agreement from col-
leagues, facilitating local research ethics committee
approval, ensuring all clinical staff involved in the care of
the patients are informed about the trial)
(ii) take responsibility for clinical aspects of the trial
locally
(iii) be represented at SMAK arthroplasty trial meetings
A part-time study nurse will be based at the collaborating
centre and will have responsibility for:
(i) keeping local staff informed about the trial and its
progress
(ii) keeping regular contact with local surgeons and co-
ordinating centre
(iii) identifying potential participants in advance of
admission
(iv) taking responsibility for ensuring complete data col-
lection
(v) getting arrangements in place for formal trial entry
(vi) facilitating progress of patients through the trial
In addition, a part time research physiotherapist will be
based at the collaborating centre and will have responsi-
bility for:
(i) assessment of functional capacity
(ii) liasing with research nurse to ensure timely assess-
ment of outcome
Discussion
There have been several trials comparing the subvastus
and medial parapatellar approaches for patients undergo-
ing primary total knee arthotomy. The major criticisms of
the sub-vastus approach are poor and unpredicatable
exposure, and difficulty with eversion of the patella
[16,17]. Some studies have shown significant advantages
in using the subvastus approach in relation to improved
quadriceps strength [18], earlier straight leg raise, and
lower analgesia use in the first week for the subvastus
group [19,20]. These studies, however, only had small
numbers and a short follow-up period, and not all
patients were blinded to the approach used.
We present the rationale and design of a pragmatic ran-
domised controlled trial comparing the sub-vastus
approach to the standard medial parapatellar approach in
terms of short and long term knee function for patients
undergoing primary total knee replacement in which the
patients are blinded to the approach used. The results of
this trial will be beneficial for Orthopaedic Surgeons
whom are under constant pressure to undertake tech-
niques which aid quicker postoperative rehabilitation,
and shorter hospital stay. The results of this trial will be
published as soon as they become available.
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